Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Isradipine · 1 trial · 6 indications
Primary outcome measures will be craving intensity to smoking cues based on a scale from 0 (No craving) to 100 (Intense craving).
| Arm | Type | Description |
|---|---|---|
| isradipine | EXPERIMENTAL | Participants will receive 15mg of immediate release isradipine. |
| placebo | PLACEBO_COMPARATOR | Participants will receive a placebo pill identical in appearance to isradipine. |
| Name | Type | Description |
|---|---|---|
| Isradipine | DRUG | Isradipine will be administered 90 minutes prior to the initiation of cue exposure. |
| Cue Exposure | BEHAVIORAL | Participants will be exposed to visual smoking cues (i.e., immersive 360 degree video environments) delivered through consumer virtual reality headset and handle cigarette packs to activate and extinguish craving. |
Inclusion Criteria: 1. 18-65 years old; 2. Willing and able to provide informed consent, attend all study visits, and comply with the protocol; 3. Daily smoker for at least one year; and 4. Currently smoke an average of at least 5 cigarettes per day. Exclusion Criteria: 1. Current diagnosis of a ...
Isradipine is a small molecule being studied for nicotine dependence, specifically to help with smoking cessation and smoking reduction. It is being evaluated in a Phase 1 clinical trial that combines the drug with virtual reality cue exposure to address smoking behaviors and craving.
Isradipine is a small molecule. Its mechanism of action in the context of nicotine dependence is being studied in clinical trials, though the specific molecular target has not been disclosed.
Isradipine is being developed by Jasper Therapeutics, Inc., a company traded on the stock exchange under the ticker JSPR.
Isradipine is in Phase 1 clinical development for nicotine dependence. It is an investigational drug and has not been approved by the FDA for this use.
Isradipine is being studied in one completed clinical trial, NCT03083353, titled "Isradipine Enhancement of Virtual Reality Cue Exposure for Smoking Cessation." The trial enrolled 78 participants in the United States and was a randomized, double-blind, placebo-controlled study.
Isradipine is the drug name used in clinical development. No alternative names have been reported for this asset.